Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001245029 | SCV001418289 | pathogenic | not provided | 2023-11-14 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr4347Ilefs*22) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (no rsID available, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with clinical features of Usher syndrome (PMID: 29625443). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV001245029 | SCV001825828 | pathogenic | not provided | 2022-11-15 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29625443) |
Genome- |
RCV003449771 | SCV004181913 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003449771 | SCV004208378 | pathogenic | Retinitis pigmentosa 39 | 2024-03-22 | criteria provided, single submitter | clinical testing |